Études cliniques

The IHA-GfK is the most renowned institut of market study in Switzerland. The results given and statements made in this presentation correspond 100% to the data collected and are fully valid.

A total of 141 patients were interviewed. After the MedicLaser + TinniTool treatment, the results were very promising. It has been shown and can be assessed that other known marketed therapies did not reach the same value.

The Soft Laser TinniTool is used to treat tinnitus in 96% of cases. 56% do not know the cause of this complaint. The main causes of the complaint were named as illness, stress and work, as well as serving in the armed forces. 42% of the respondents had used the Soft Laser TinniTool for 3 months. For 65% of those affected, the complaint had been reduced by up to 25%, for 20% between 25% and 49% and, for 9%, by 50%-100%. The longer the period of use, the greater the success of the treatment. On a scale of 0 to 9, satisfaction with the Soft Laser TinniTool achieved an over average of 4.8. Satisfaction with the Soft Laser TinniTool increased in proportion to the length of use as well as with the extent to which the complaint had been reduced. 18% also used the Soft Laser Tinnitool for other forms of treatment, such as for joints, acne, scars and arthrosis. The satisfaction of those respondents who had also used the Soft Laser TinniTool for other forms of treatment achieved overall a good score of 6.38 on a scale of 0 to 9. Overall satisfaction with the Soft Laser TinniTool increased with length of use. 54% of the respondents would buy the Soft Laser TinniTool again. 67% would recommend the Soft Laser TinniTool to others.

L’étude sans aucun doute la plus pertinente concernant le traitement par TinniTool Earlaser a été réalisée en Italie. Dans le cadre d’une étude en double aveugle, le centre de traitement des acouphènes de la division ORL de la clinique de Piacenza a traité 46 patients (27 hommes et 19 femmes) souffrant d’acouphénie, avec le TinniTool EarLaser. Ces lasers à lumière froide disposent d’une puissance de plus de 5mW, et présentent une longueur d’onde de 650 nm.

Les mesures ont été évaluées à l’aide du système d’évaluation standardisé THI (Tinnitus Handicap Inventory –selon Dr. Newman). L’amélioration constatée après les traitements était significative. La différence entre le groupe testé et le groupe placebo était elle aussi significative. Au total, les résultats ont montré une amélioration dans 88 % des cas. Chez 62 % des patients traités, l’amélioration était très significative (d’une catégorie selon le THI). Dans 11,6 % des cas, l’amélioration a même été tout à fait remarquable (de 2 catégories selon le THI).

Récemment, la thérapie laser à basse énergie devient une alternative thérapeutique pour le traitement des acouphènes chroniques et la perte de l’audition neurosensorielle. Lors de cette étude clinique 32 patients souffrant d’acouphénie ont été traités avec le Tinnitool Earlaser. Tous les patients souffraient depuis plus de 3 mois d’acouphènes constants. Quelques-un d’entre eux faisaient de l’hypertension, étaient diabétiques, souffraient en plus de perte de l’audition où de maladie de coeur chronique. Le Softlaser disposait d’une puissance de 5 milliwatts et d’une longueur d’ondes de 650 nanomètres. La durée d’utilisation était de 20 minutes par jour.

Les résultats montrent une amélioration aussi bien pour l’intensité des acouphènes que pour la perte du degré de l’audition. Dans 88% des cas une amélioration supérieure à 25% a été constatée. Chez 47% des patients, les acouphènes avaient même disparus complètement. Dans 66 % des cas une amélioration de la perte de l’audition de plus de 5 décibels a été constatée au niveau de fréquence de 250-8000 Hz et chez 10% des patients une amélioration de plus de 20 décibels a été constatée. En conclusion de cette étude clinique, il peut être confirmé que la thérapie laser à basse énergie avec le TinniTool Earlaser est une méthode de traitement très effective des acouphènes et de la perte de l’audition neurosensorielle.

In a double-blind placebo-controlled study low-level-laser light was applied to 175 patients with chronic tinnitus. The patients received 3 single irraditations with different diode-laser with 635-830 nm and dosages from 4 to 100 Joule/cm2.

Low-level laser therapy for chronic tinnitus has been well tolerated without side effects. In general higher dosages caused to a stronger attenuation of tinnitus.

In comparison to placebo: - tinnitus loudness is improved by laserlight of 780 nm - tinnitus is attenuated by laserlight between 690 and 830 nm concerning visual analogue scales of 5 different parameters. - total tinnitus score has been improved by irradiation with laserlight of 635 up to 830 nm. Regarding those results, tinnitus-laser offers an innovative and secure way of effective tinnitus treatment in patients with chronic tinnitus. Tinnitus-lasers are a new therapeutic system for chronic cochlear tinnitus without risk of side-effects.

Transmeatal cochlear laser (TCL) treatment has recently been proposed as a therapeutic procedure for cochlear dysfunction such as chronic cochlear tinnitus or sensorineural hearing loss. The aim of this study was to investigate whether TLC has any influence on the central nervous system using functional MRI with healthy young adults. The laser stimulation device was placed on the tympanic membrane of both ears. A laser stimulation run and a placebo run were performed in random order. The participants were unable to differentiate between verum and placebo stimulation. In the comparison of verum to placebo runs, we observed significant activations within the left superior frontal gyrus, the right middle and medial frontal gyrus, the right superior parietal lobule, the left superior occipital gyrus, the precuneus and cuneus bilaterally, the right anterior and the left and right middle and posterior cingulate gyrus and the left thalamus. This network of brain areas corresponds well to results from previous PET studies of patients with tinnitus. Though TCL seems to have a clinically measurable effect on the central nervous system the neurophysiological mechanism leading to the observed activated neuronal network remains unknown.

has performed an ex-vivo laser penetration study. Based on these findings it was possible to calculate the energy needed to obtain a dose of 4 J/cm2 in the cochlea itself. Irradiation via the mastoid showed values 103 to 105 times smaller (depending on wavelength) than irradiation through the tympanic membrane. 35 patients were treated five times within 2 weeks. One group was irradiated with 635 nm diode laser, the other with 830 nm diode laser. By self-assessment around 40% of the patients reported a slight to significant attenuation of the tinnitus loudness of the irradiated ear.

37 patients suffering from tinnitus (age 18-86 years) were treated in three ways: 1. Rehabilitation: mobilisation, physical training, physiotherapy. 2. Same as 1 but with placebo laser added. 3. Same as 1 but with functional laser added. Laser used was 830 nm 300 mW. 2-3 treatments per week were given, total 10 treatments. Treatment protocol: 90 J/cm2 CW on mastoideus, 45 J/cm2 5 Hz on mastoideus, 50 J/cm2 CW on acoustic duct, 25 J/cm2 5 Hz on acoustic duct. Tebokan Egb 761 ginko medication was added to treatment. Results were classified as no effect/less than 50% relief/more than 50% relief/no more tinnitus. The percent wise outcome for the three groups was: 1.29.4/44.1/17.6/8.9 2. 25.8/48.4/25.8/0 3. 19.4/19.4/35.5/25.8 Auris Nasus Larynx. 1997; 24 (1): 39-42.

In an extended study over 3 years Prochazka [1263] evaluated the effect of laser in a group of 200 patients. These patients were taking gingko biloba preparations (73%) or Betahistadine (39%) and also had physical therapy, mainly directed at the neck vertebrae. Laser therapy was performed with a 300 mW GaAlAs laser, 75 J/cm2 into the ear and 135 J/cm2 behind the ear. The outcome was: no more tinnitus 26%, more than 50% relief 43%, less than 50% relief 15%, no effect 16%. In addition a group of 31 patients were selected for a double blind study where the same therapy as above was performed, but one group received placebo laser. At 6 months the outcome was as follows, with laser/no laser: no more tinnitus 25.8%/0.0%, more than 50% relief 35.5%/25.8%, less than 50% relief 19.4%/48.4%, no effect 19.4%/25.8%.

I risultati terapeutici ottenuti con LLLT sono stati confrontati con i risultati di un gruppo placebo; n definitivo sarà di 30 pazienti per gruppo, attualmente dati riferiti a n=13 per gruppo terapeutico e n=16 per gruppo controllo. Studio randomizzato, in doppio cieco; laser del gruppo placebo del tutto identico al gruppo che effettuava terapia ma non emettente luce terapeutica. Applicazione di LLLT domiciliare con TinniTool per 20 minuti al giorno per 4 mesi. Caratteristiche del laser: 5mw, 650 nm, energia totale assorbita per applicazione 6 Joule/c.

Conclusioni: Miglioramento delle caratteristiche “fisiche” dell’acufene; Loudness diminuita. Peraltro non variazioni statistiche dei valori di THI e delle scale VAS. Nessun effetto collaterale registrato. Acufene dopo terapia è più facilmente mascherabile e diminuiscono i pazienti affetti da iperacusia. Questi ultimi dati suggeriscono il possibile impiego della LLLT associata alla TRT per migliorare i parametri che maggiormente ostacolano il successo della terapia con l’arricchimento sonoro.
(Sur demande cette publication est disponible en langue italienne.)

Tinnitus ist eine lästige und oft schwächende Beschwerde neuro-otologischen Ursprungs, aber unbestimmter Ursache. Viele Behandlungsmethoden wurden erprobt, aber bisher war keine wirklich erfolgreich. Die vorliegende vorläufige Studie berichtet über einen Blindversuch mit 40 Patienten, je 20 in einer Versuchs- und in einer Kontrollgruppe, die mit der Lasertherapie in Kombination mit der Einnahme eines Ginkgo-Biloba-Extraktes behandelt wurden.

Alle 40 Patienten erhielten eine Biloba-Extrakt-Injektion, aber nur die 20 Versuchspatienten bekamen tatsächlich Laserbestrahlungen, acht Tage lang täglich acht Minuten.

Die Kontrollgruppe erhielt nur eine vorgetäuschte Bestrahlung. Von der Versuchsgruppe gaben 50 % an, dass sich ihr Tinnitus um mehr als 10 dB reduziert habe, verglichen mit 5 % in der Kontrollgruppe sowohl bei der Selbsteinschätzung als auch bei den audiometrischen Ergebnissen.

Obgleich es sich nur um einen vorläufigen Bericht handelt, sind die Ergebnisse sehr ermutigend, und die Autoren empfehlen diese kombinierte Fotochemotherapie als vielversprechende Behandlung des Tinnitus.

Objective: To evaluate effectiveness of 5 mW laser irradiation in the treatment of chronic tinnitus. Study design: Prospective, randomised, double-blind study. Methods: This investigation included 66 ears in 45 patients with chronic unilateral or bilateral tinnitus. A 5mW laser with a wavelength of 650 nm, or placebo laser, was applied transmeatally for 15 minutes, once daily for a week. A questionnaire was administered which asked patients to score their symptoms on a five-point scale, before and two weeks after laser irradiation. A decrease of one scale point, regarding the loudness, duration and degree of annoyance of tinnitus, was accepted to represent an improvement.
Results: The loudness, duration and degree of annoyance of tinnitus were improved, respectively, in up to 48.8, 57.7 and 55.5 per cent of the patients in the active laser group. No significant improvement was observed in the placebo laser group.
Conclusion: Transmeatal, low power (5 mW) laser irradiation was found to be useful for the treatment of chronic tinnitus.

has investigated the effect of infrared laser applied directly into the meatus acousticus, 21 J, once a week for 10 weeks. The result of this non-controlled study is as follows: 26% of the patients reported improved duration, 58% reduced loudness and 55% reported a general reduction in annoyance.
The same author [687] has also examined the effect of light on the cochlea using guinea pigs. Direct laser irradiation was administered to the cochlea through the round window. The amplitude of CAP was reduced to 53-83% immediately after the onset of irradiation. The amplitude then returned to the original level. The results of this investigation suggest that laser therapy might lessen tinnitus by suppressing the abnormal excitation of the eighth nerve of the organ of Corti.

examined 120 patients with an average duration of tinnitus of 10 years. The patients underwent pure-tone audiometry, speech audiometry and objective audiometry tests. The intensity and frequency of tinnitus was also determined. EGb 761 was administered 3 weeks before the start of laser therapy. The patients underwent 10 sessions of laser therapy, each lasting 10 minutes. An improvement in tinnitus was audiometrically confirmed in 50.8% of the patients; 10 dB in 18, 20 dB in 22, 30 dB in 10, 40 dB in 6 and 50 dB in 5 patients.